Physician profile
Troy Kepper
NPI 1225547599
$23,708.13
in general payments reported to CMS, 2019-2025
35 companies · $6,072 in 2025
The $6,072 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,936 · 2022: $3,955 · 2023: $4,212 · 2024: $5,534 · 2025: $6,072.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Consulting Fee: $600 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,018.03 |
| Consulting Fee | $600.00 |
| Education | $199.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,057.97 | 2021-2025 | Farxiga, Brilinta, Wainua |
| Bayer Healthcare Pharmaceuticals INC. | $2,436.98 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,018.41 | 2021-2025 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $1,737.93 | 2021-2025 | Uptravi, Opsumit, Opsynvi |
| Pfizer INC. | $1,552.38 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,534.45 | 2021-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $1,410.77 | 2021-2025 | |
| Abbott Laboratories | $1,122.46 | 2021-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Alnylam Pharmaceuticals INC. | $1,100.79 | 2021-2025 | Amvuttra, Onpattro |
| Amgen INC. | $1,091.82 | 2021-2025 | Repatha, Krystexxa, Repatha |
| United Therapeutics Corporation | $938.81 | 2021-2025 | Tyvaso, Orenitram, Orenitram |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $868.93 | 2021-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $821.80 | 2021-2025 | Verquvo, Winrevair, Capvaxive |
| Cvrx, INC. | $788.41 | 2023-2025 | Barostim Neo System |
| Novo Nordisk INC | $394.10 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $346.77 | 2021-2024 | Xarelto |
| Aop Health US, LLC | $279.95 | 2025 | Rapiblyk |
| Kestra Medical Technology Services, INC. | $248.18 | 2025 | Assure Wcd |
| Scpharmaceuticals INC. | $211.85 | 2023-2025 | |
| Lexicon Pharmaceuticals, INC. | $196.31 | 2023-2024 | Inpefa |
| Daiichi Sankyo INC. | $185.49 | 2023-2025 | Injectafer |
| Amarin Pharma, INC. | $174.46 | 2021-2022 | |
| Boston Scientific Corporation | $166.86 | 2021-2024 | Watchman Flx, Watchman Access System |
| Medtronic, INC. | $151.97 | 2022 | |
| Abiomed | $147.10 | 2023-2024 | Impella |
| Impulse Dynamics (USA) INC. | $126.20 | 2022-2024 | Optimizer, Optimizer |
| Regeneron Healthcare Solutions, INC. | $103.70 | 2025 | Dupixent |
| Bridgebio Pharma, INC. | $97.21 | 2025 | Attruby |
| Lilly USA, LLC | $91.04 | 2024 | |
| Genzyme Corporation | $76.50 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $74.08 | 2021-2024 | Livalo |
| Kiniksa Pharmaceuticals International, Plc | $67.71 | 2024 | Arcalyst |
| Esperion Therapeutics, INC. | $53.26 | 2024-2025 | Nexletol |
| Philips North America LLC | $19.26 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Kiniksa Pharmaceuticals, LTD. | $14.22 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Troy Kepper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.